ProductLife Group Strengthens Global Presence with Acquisition
ProductLife Group (PLG) is excited to announce a significant milestone in its journey of growth and innovation—its acquisition of IntiQuan AG. As a global leader in regulatory and scientific consulting for the life sciences, this strategic acquisition reinforces PLG's commitment to advancing drug development capabilities.
IntiQuan: A Leader in Pharmacometric Services
Since its inception in 2015, IntiQuan has built a solid reputation for delivering exceptional pharmacometric and statistical modeling services exclusively for the biopharmaceutical sector. This acquisition allows PLG to bolster its portfolio, providing a richer array of solutions tailored for biopharmaceutical companies, focused on minimizing risks, reducing costs, and shortening timelines in drug development.
Innovative Solutions for Drug Development
The coming together of these two organizations marks a pivotal enhancement in the services offered by PLG. With IntiQuan's expertise in pharmacokinetics and pharmacodynamics, population pharmacokinetics, and biosimulation, clients can now expect ambitious strategic consulting options that dramatically improve the overall drug development process. IntiQuan's proven track record in translating complex data into actionable insights across various therapeutic areas exemplifies its value-add in this united effort.
Strategic Significance of the Acquisition
In the competitive landscape of drug development, having a fully integrated global platform is increasingly vital. PLG’s acquisition of IntiQuan is a step closer to achieving this goal. As plans for further expansion unfold in key markets around the world, especially in the US and Europe, the collaboration aims to establish PLG as a preeminent global provider of comprehensive drug development services.
Voices from Leadership
Xavier Duburcq, PLG's CEO, emphasized the ideal fit of IntiQuan within their organization, stating, "We are thrilled to welcome the IntiQuan team to our fold. Their specialized expertise will enhance our support to clients throughout their drug development journeys. By integrating pharmacometrics and model-informed drug development insights, we not only facilitate faster decision-making but can sometimes even streamline clinical trials altogether."
Dr. Henning Schmidt, the founder of IntiQuan, echoed this sentiment, highlighting the importance of their united capabilities in accelerating market access for groundbreaking medicines. He noted, "Together, we will aid in significantly reducing both the time to market and the cost associated with research and development, which is ultimately aimed at benefiting patients worldwide."
Complementing Strengths and Goals
Dr. Stefan Wetzel, CEO of IntiQuan, also expressed enthusiasm regarding the synergy between the two teams. With a culture centered around innovation and customer focus, the integration promises to enhance the quality of solutions provided, especially in regulatory services, addressing a broader range of customer needs.
Advisory Support for the Acquisition
The acquisition was guided by a team of expert advisors. Capitalmind Investec served as M&A advisor for IntiQuan, while PLG received support from DDA & Company and Hoffman & Partner as M&A advisors along with RSM for financial and tax advice, and CMS Von Erlach Partners for legal counsel. Such robust advisory support reflects the significance of this merger in the life sciences sector, illustrating the high expectations set for this partnership.
About ProductLife Group
ProductLife Group’s overarching mission is to facilitate patient access to safe and effective healthcare solutions. Its global reach covers over 150 countries, cementing PLG's position as a strategic partner for the development, market introduction, and lifecycle management of diverse product portfolios. With a commitment to long-term innovation and client collaboration, PLG seeks to continually enhance the value offered to teams and clients alike.
About IntiQuan
IntiQuan AG provides top-tier solutions in pharmacometrics and quantitative systems pharmacology, focusing on the optimization of drug development. Established in Switzerland, their expertise in complex data integration positions them as a crucial player in furthering precision medicine and patient safety.
Frequently Asked Questions
What does ProductLife Group do?
ProductLife Group is a global leader in regulatory and scientific consulting for the life sciences sector, dedicated to improving drug development processes.
Why did ProductLife Group acquire IntiQuan?
The acquisition of IntiQuan enhances PLG's capabilities in pharmacometrics, enabling them to provide advanced solutions in drug development.
What services does IntiQuan specialize in?
IntiQuan specializes in pharmacometric services, statistical modeling, simulation, and quantitative systems pharmacology tailored for the biopharmaceutical industry.
How will this acquisition impact clients?
Clients can expect improved support and access to a broader range of innovative solutions that enhance drug development efficiency and effectiveness.
Is PLG expanding its operations?
Yes, PLG has plans for further expansion, particularly in the US and European markets, to strengthen its global presence.
